Szofia Bullain

New Capabilities

Leading diranersen's move to late-stage trials

For decades, nearly every Alzheimer's drug that reached patients aimed at one target: a sticky protein called amyloid. On July 14, 2026, Biogen showed the first clinical evidence that hitting a different protein, tau, can also slow the disease.

Updated Jul 14